Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Cell Transplantation Using iPS Cell-Derived Renal Progenitors Effective for Acute Kidney Injury in Mice: Kyoto Univ., Astellas
July 23, 2015
- PIII Study of Opdivo in Renal Cell Carcinoma Ends Early Based on Favorable Results: Ono, BMS
July 23, 2015
- JCR, Eisai Collaborate for Blood-Brain Barrier Penetration Technology
July 22, 2015
- Ono Files Opdivo for Non-Squamous NSCLC
July 22, 2015
- Japanese Contract Manufacturing Market Grows to 290 Billion Yen in FY2013: Yano Research
July 21, 2015
- Eisai to Transfer US Subsidiary Plant to Biogen
July 21, 2015
- GSK, Pola Pharma Join Hands for Marketing of Acne Vulgaris Treatment Duac
July 21, 2015
- Kyowa Kirin R&D Exec Lauds Sakigake System, but Calls for More Incentives
July 17, 2015
- Deltyba Effective in Extensively Drug-Resistant Tuberculosis: Otsuka
July 17, 2015
- Kyowa Kirin Grants AZ Option Rights to Commercialization of Benralizumab in Japan
July 17, 2015
- ASCO Immunotherapy Roundup - 3: AZ Set to Harness Rich Pipeline to Pursue Combo Strategy
July 16, 2015
- Quintiles to Make Full-Fledge Entry into Regenerative Medicine, by Opening New Office in Kobe
July 16, 2015
- Sumitomo Dainippon Ties Up with Servier for Commercialization of Latuda in Australia
July 16, 2015
- Takeda Files NDA for Novel Proteasome Inhibitor Ixazomib in US
July 16, 2015
- As 80% Era Looms, 3 Generic Majors Will Emerge as Dominant Suppliers: Sawai
July 16, 2015
- Kowa Grants Chugai Exclusive Marketing Rights in Japan for Peretinoin for Prevention of Recurrence of HCC
July 15, 2015
- ASCO Immunotherapy Roundup - 2: Chugai Has High Hopes for Atezolizumab Combos with Group Portfolios
July 14, 2015
- Takeda Announces Its Plan to Improve Business Practices; Will Add an Outside Expert to Review Board
July 14, 2015
- US FDA Approves Novel Antipsychotic Agent Rexulti: Otsuka, Lundbeck
July 14, 2015
- Merck Serono Names Former Allergan Japan President Leo Lee as New President
July 14, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…